ISSN 2664-4142 (Print) & ISSN 2664-6749 (Online)
South Asian Research Journal of Pharmaceutical Sciences
Abbreviated Key Title: South Asian Res J Pharm Sci

| Volume-6 | Issue-3 | May-Jun 2024 | **DOI: 10.36346/sarjps.2024.v06i03.007**

Original Research Article

A Comprehensive Review Article on Dengue Fever

Akshata V. Zende[1*], Yogesh A. Shinde[2], Rutuja R. Sonwalkar[1], Priyanka B. Parekar[3]

[1]Delonix Society's Baramati College of Pharmacy, Barhanpur, Baramati, Daund, Patas Road, India 413102
[2]Yashoda Shikshan Prasarak Mandal, Yashoda Technical Campus Satara, Maharashtra, India 415015
[3]Chetana Foundation, Chetana College of Pharmacy, Indapur, Pune, Maharashtra, India 413106

***Corresponding Author:** Akshata V. Zende
Delonix Society's Baramati College of Pharmacy, Barhanpur, Baramati, Daund, Patas Road, India 413102

Article History
Received: 02.05.2024
Accepted: 10.06.2024
Published: 20.06.2024

Abstract: Dengue fever is a contagion- caused complaint that is spread by mosquitoes. Dengue is an acute viral illness caused by RNA contagion of the family Flaviviridae and spread by Aedes mosquitoes. A womanish Aedes aegypti mosquito carrying a blood- mess from a mortal host through her honker which penetrates the host's skin. That occurs in tropical and tropical areas of the world. The complaint is now endemic in farther than 100 countries in the WHO Regions, analogous as the Americas, Africa, the Middle East, Asia, and the Pacific islands & also other countries who can suffered these world wide spread complaint. About half of the world's population is now at trouble of dengue with an estimated 100 – 400 million infections being each time. The severe form of dengue fever, also called dengue hemorrhagic fever, can beget serious bleeding, a unlooked-for drop in blood pressure (shock) and death. Symptoms include high fever, severe headache, joint and muscle pain, nausea, and puking. Treatment for dengue fever includes supportive care, analogous as rest and fluids. The complex pathogenesis of thrombocytopenia and increased vascular permeability in dengue illness is also mooted. The composition give a detailed overview on dengue contagion infection, medium, symptoms, discriminative opinion & prevention & treatment.

Keywords: Vectors, Structure & Organization, History & Epidemiology, Life Cycle, Transmission, Dengue fever, Undifferentiated Fever, Dengue Haemorrhagic Fever, Dengue Shock Syndrome, Thrombocytopaenia, Treatment, Vaccines, Herbal and Home Remedies.

INTRODUCTION

Preface Dengue is an important arthropod- borne viral infection which poses a global public health problem. An estimated3.9 billion people in 128 countries are at threat of infection [1]. And dengue contagion infections regard for nearly 500,000 hospitalizations annually [2]. Dengue is transmitted generally by the domestic Aedes aegypti mosquito, and to a lower extent, the peridomestic Aedesalbopictus mosquito [3]. The four mosquito- borne dengue contagions are now aboriginal in civic and pastoral areas in far further than 100 tropical and sub-tropical countries with annually 50 – 100 million estimated cases.4 Dengue contagions are members of the family Flaviviridae and are of 4 serotypes (DEN- 1, DEN- 2, DEN- 3, DEN- 4). This mosquito- borne infection can be asymptomatic or lead to an undifferentiated fever (UF), dengue fever (DF) or dengue hemorrhagic fever (DHF) with tube leakage, which conceivably can develop into hypovolemic shock, dengue shock pattern (DSS). 1 Dengue and dengue- suchlike pandemics do in the Americas, southern Europe, northern Africa, the eastern Mediterranean Sea, Asia and Australia and on colourful islets in the Indian Ocean, the southern and central Pacific Ocean and the Caribbean Sea.1, 2. There are four distinct dengue virus (DENV) serotypes that partake antigenic connections (DENV- 1, DENV- 2, DENV- 3 and DENV- 4) [4]. Principle Transmission vectors are arthropods of the Aedes (Ae.) kidney, especially Aedes aegypti [5]. Short term changes in Temperature, rush and moisture are frequently identified with dengue prevalence. Other important factors Include population growth, urbanization, lack of Sanitation, increased long distance trip and ineffective Mosquito control [6]. All age groups and both relations are Affected [7]. The pathogenesis of dengue contagion infection and severe dengue instantiations is veritably complex and not fully understood. The pathophysiological hallmark of DHF/ DSS is tube leakage and crazed haemostasis. Indeed after being

apprehensive of tube leakage in dengue since the last five decades, the clear- cut medium of this incarnation stills remains obscure [8]. There's no specific treatment for dengue other than probative measures and judicious fluid remedy. Clinical trials have assessed colourful remedial options with minimum success over the last 50 times.

DENV Vectors:



Fig 1: Types of DENV Vectors (Colour Online)

Structure of dengue organization:

Electron micrographs revealed that dengue virions are globular and characterized by a fairly smooth face, with a periphery of roughly 50 nm, a well- organized external protein subcaste on the face of a lipid bilayer, and an inner nucleocapsid core (Kuhn *et al.*, 2002) (Fig 2) [9].



Fig. 2: Enveloped and spherical dengue virion with different structural proteins and (B) Cryo-electron Microscopic structure of the dengue virus (DENV-4). The black triangle shows the icosahedral asymmetric unit. E protein dimers are in blue. Three E proteins reside in one asymmetric unit. Scale bar = 100 Å (Kostyuchenko *et al.*, 2014) [Colour online.]

History and Epidemiology:

Contagion infects humans in further than 100 countries each time, with roughly 3.6 billion people at threat (Diamond and Pierson 2015) [10]. During the last 50 times, the Prevalence of dengue has increased30-fold (CDC 2014). DENV Pandemics do annually in the Americas, Asia, Africa, and Australia, and also affect trippers. From aboriginal regions also including India. The first dengue outbreak was reported in 1779 in Jakarta, Indonesia and Cairo, Egypt (Wu *et al.*, 2011) [11] The Worldwide average number of suspected or verified Dengue cases reported to the WHO (2010 – 2016) (see WHO 1997) (12) is presented in Fig 3. Dengue pandemics were reported in East, West, and South Africa from the morning of the 19th century (Amarasinghe *et al.*, 2011; Were 2012) [13, 14].



Life Cycle:

Primarily, the DENV was transmitted via sylvatic cycles in Asia and Africa by Aedes mosquito and the inhuman primates, with occasional appearances of mortal populations [15]. Still, currently, the global spread of DENV follows its emergence of all types of transmissions (e.g., sylvatic cycles and perpendicular mosquito to mosquito). Therefore, its primary life cycle entirely involves the transmission between Aedes mosquitoes and humans [16]. One report suggests that tykes or other creatures may act as incidental hosts and may serve as budgets of DENV infection [17]. Life cycles of mosquitoes have been shown in Figure 4. An external train that holds a picture, illustration.



Figure 3: Mosquito life cycle (Colour Online)

Transmission:

After original midgut infection, DENV distributes systemically through the body depression (generally known as hoemocel) of Aedes vectors, after that way disseminates in secondary apkins. The time taken between original midgut infection and consecutive transmission of DENV by its vector (e.g., Ae. Aegypti) is nominated as foreign incubation period (7 to 14 days at 25- 30 °C). DENV stays in the midgut of the vectors which it may be due to the viral genome being stable then [18]. Eventually, an infection of the salivary glands and the release of virions into the host's slaver do throughout the DENV transmission to the host [19]. Blood cells and tube are important media for the four serotypes of DENV spreading into the host. A relation of sphere III from the envelope glycoprotein of DENV- II with mortal tube proteins has been linked by Huerta *et al*., [20, 20]. C protein is a foremost structural element of DENV that's localized in the cytoplasm and capitals [21, 22].

The nuclear localization of this protein is allowed to be pivotal for its well- organized replication [21, 23]. RNA in the salivary galnds of Ae. Aegypti, indicating an active replication of DENV in its vector previous to transmission [24]. DENV itself encodes RNA-dependent RNA polymerases, and the infection cycle of this contagion is catalyzed by other cellular factors [25]. Aninteraction between DENV nonstructural protein 4A (NS4A) and host cellular vimentin has been demonstrated in localizing and concentrating the viral replication complex at the perinuclear point, in consequence aiding well- organized replication of viral RNA [26].



Fig 4: Transmission of Dengue Virus (Colour Online)

Mechanism:

When a mosquito carrying DENV bites a person, the contagion enters the skin together with the mosquito's saliva. It binds to and enter the white blood cells, and reproduces inside the cells while They move throughout the body. The white blood cells respond by producing a number of signalling Proteins (analogous as interferon) that are responsible for multitudinous of the symptoms, analogous as the fever, the flu- Like symptoms and the severe pains. In severe infection, the contagion product inside the body is important Increased, and multitudinous farther organs (analogous as the liver and the bone gist) can be affected, and fluid from the bloodstream leaks through the wall of small blood vessels into body depressions.

As a result, lower Blood circulates in the blood vessels, and the blood pressure becomes so low that it can not supply Sufficient blood to vital organs. likewise, dysfunction of the bone gist leads to reduced figures of platelets, which are necessary for effective blood clotting; this increases the threat of Bleeding, the other major complication of dengue. Severe complaint it isn't entirely clear why secondary infection with a different strain of DENV Places people at threat of dengue hemorrhagic fever and dengue shock pattern. The most extensively Accepted thesis is that of antibody-dependent improvement (ADE) [27].



Fig 5: Mechanism of Dengue Virus (Colour Online)

Pathogenesis:

1. Thrombocytopaenia:

Thrombocytopenia results from flash bone gist repression and increased supplemental destruction of platelets during the febrile And early convalescent phases of the complaint, and results In platelet counts as low as 5,000 per ml(compared With roughly 200,000 platelets per ml in healthy individualities) [28, 29]. Remarkably, in the bone gist, early repression of the product of all blood cell types occurs during the early febrile phase of DENV infection [30, 31].

2. Coagulopathy:

The disabled haemostas is that accompanies DHF/ DSS involves a series of differences in the Coagulation system that disrupts the regulation of clot conformation. For illustration, an increase in actuated partial Thromboplastin time (APTT; which measures time to Clot conformation) and a reduction in the position of fibrinogen (a factor that promotes Clot conformation) are fairly harmonious findings in DHF/ DSS [32-34] Recent reports have Shown that NS1 binds to thrombin in vivo to form NS1 – Thrombin complexes. In addition, in vitro, rNS1 inhibits Prothrombin activation and prolongs APTT in mortal Platelet-deficient plasma [35].

Clinical manifestation: Dengue fever is characteristic or a symptomatic. Clinical complaint onsets 4- 6 days after pestilent mosquito bite.

Symptomatic vs Asymptomatic: (Characteristics)

Asymptomatic Infections itinerant cases with characteristic DENV infections have viremia situations that are plainly likely to render them contagious to mosquitoes [36]. Individualities who are asymptomatic with a DENV infection also have sensible situations of contagion circulating in the blood [37, 38], but the question remains open as to whether or not inapparent DENV infections have high enough viremias to be contagious. Because inapparent DENV infections are common [39, 40], it follows that they could play a part in the conservation of DENV in its natural transmission cycle, should their viremias be above the contagious threshold position.



Fig 6: Classification of Dengue Viral Infection (Colour Online)

Sign & Symptoms: Symptoms of dengue typically last 2–7 days. Most people will recover after about a week.

Most common symptoms of Dengue: 1. Undifferentiated fever; 2. Classical dengue fever; 3. Dengue haemorrhagic fever; 4. Dengue shock syndrome



Fig 7: Symptoms of Dengue Fever (Colour Online)

1. Undifferentiated Fever:

Acute undifferentiated fever (AUF) is constantly seen in clinical practice but the Etiology isn't always set up. The condition may be distinguished from fever of Unknown origin (FUO) by fever duration, Progression of illness and underpinning Causes (Phuong *et al*., 2006; Efstathiou *et al.*, 2010; Abrahamsen *et al*., 2013) [41-43]. In FUO, fever must be present for at least Three weeks (Petersdof and Beeson, 1961; Durack and Street, 1991) [44, 45]. Cases with AUF have a more limited duration of fever and numerous of the occurrences resolve spontaneously and are presumed to be due to tone- limiting infections (Thangarasu *et al.*, 2011) [46]. Acute fever requires careful evaluation because it could be the first sign of A potentially serious infection.

2. Classical dengue fever:

Classical DF is a clinical pattern characterized by an a brupt onset of fever, which may be accompanied by chills, delicacy, headache, retro- orbital pain, backache, myalgia, arthralgia, anorexia, nausea and vomiting, diarrhea and a

generalized maculopapular rash. Progressive leukopenia and thrombocytopenia are common during this febrile period [47]. Petechiae, goo bleeding, and epistaxis may also do. Symptoms start 4 – 10 days after the bite from an infected mosquito and generally last for 2 – 7 days. Original dengue contagion infections are generally mild or subclinical, although cases of severe primary dengue have been reported [48].

3. Dengue Heamorrhagic fever:

Tube leakage in DHF is important to manage with aggressive intravascular volume starvation to help or reverse hypovolemic shock. In mild cases, particularly when medical attention is entered beforehand, oral rehydration may be sufficient. Still, in cases with established intravascular fluid loss, intravenous fluid administration is recommended. Blood transfusion is applicable in cases with significant bleeding [27].



Fig 8: Phases of Infections in Dengue Hemorrhagic Fever (Colour Online)

4. Dengue Shock Syndrome:

Substantial Tube losses may do, leading to the potentially fatal dengue shock pattern (DSS). Although grown-ups do experience shock, vascular leakage is generally more severe in youthful children [49], and in aboriginal areas DSS is seen primarily in the pediatric population. Thrombocytopenia and coagulation dislocations also do, and a variety of bleeding instantiations ranging from minor skin petechiae to major mucosal bleeding may be seen. Neither vaccines nor specific curatives are presently available; careful clinical observation and judicious use of intravenous fluid remedy, in particular critical shock reanimation for DSS, are the foundations for successful operation [50].

Lab Diagnosis: Detection of dengue:

Discovery of dengue infection may be done in two ways laboratory opinion from a culture or blood sample and discovery of anti-dengue antibodies in serum/ tube. DENV is set up in serum, tube, or circulating blood cells or towel during the first 1 to 7 days, utmost meetly during the period of fever. Contagion or viral RNA can be insulated for discovery within that period by rear transcriptase real- time PCR (RT- Q- PCR) amplification or by conventional PCR, using applicable oligo- nucleotide manuals. Quantitative PCR (Q- PCR) can be used to quantify the viral cargo in body fluids. Serological discovery depends on the demonstration of anti-dengue immunoglobulin M (IgM) antibodies or by non-structural protein 1(NS- 1) antigen in the serum/ tube of cases using either enzyme- linked immunosorbent assay ELISA) or vulnerable chromatographic- grounded rapid-fire card tests (Fig 6). The five introductory serological tests that are more accurate in diagnosing dengue infection are hemagglutination- inhibition (HI), complement fixation(CF), neutralization test (NT), IgM prisoner enzyme- linked immunosorbent assay (MAC- ELISA), and circular IgG ELISA Tourniquet Test. The NS1 and IgM diagnostics aren't completely dependable because of cross-reactivity with other flavivi- ruses (e.g., Zika contagion) (Wellekens *et al*., 2020) [51].

1. Hemagglutination- inhibition test (HI):

Test antibody against hemagglutinin spike of virus. For numerous times, the HI was the standard system used in dengue contagion opinion due to its high degree of perceptivity and fairly easy prosecution. Dengue-specific antibodies are detected for numerous times (48 times or further), being of great value for seroepidemiological studies and to separate primary from secondary infections. In primary infections, acute phase antibodies are detected from the fifth or sixth day of symptoms, generally when antibody titers are above 110. The antibody titers of convalescent phase samples are generally below 1640 in primary infections. On the other hand, in secondary or tertiary infections dengue-specific antibodies are readily detected, and there's a rapid-fire increase of the titer during the first days of the infection, generally to a titer advanced than 5120. Therefore, a titer of 11,280 or advanced in samples collected during the acute phase or at the morning of the convalescent phase of the complaint is an suggestion of a dengue secondary infection. The high situations of antibodies remain constant for two to three months in some cases when the titer of antibodies begins to fall. The main disadvantages of the HI test are its lack of particularity, the need for paired samples, and the incapability to identify the infecting contagion serotype [52].

2. Complement Fixation Test (CF):

Complement Obsession test (CF) The CF is generally not used for routine dengue opinion, since it's fairly difficulty to perform, taking largely good and trained labor force to achieve good results. The test is grounded on the principle that the complement will be consumed during the antigen- antibody response. The antibodies detected for CF generally appear latterly than HI antibodies and they persist for short ages, being of limited value for seroepidemiological studies. They're veritably specific in the primary infections, contributing to the determination of the infecting serotype, as demonstrated by the monotypic responses observed in primary infections [52].

3. MAC- ELISA (IgM prisoner ELISA):

Detects Dengue specific IgMantibody.it can distinguish primary infection from secondary infection. In primary infection portion of IgM to IgG is lesser than1.5 Serological discovery grounded on IgM- prisoner ELISA and IgG ELISA or a hemagglutination inhibition Test have come the new norms for the discovery and Isolation of primary and secondary dengue contagion Infections. RT – PCR, which has the advantage of detecting dengue contagion in acute- phase serum, represents a system for the opinion and isolation of the four dengue contagionsero types. Because the individual perceptivity range is 90 – 93 in IgM- prisoner ELISA and 80 – 100 in RT – PCR, the individual perceptivity of RT – PCR in combination with IgM- prisoner ELISA will be Advanced than 90. This system also appears to be useful for probing the pathogenesis of dengue illness, 14 and may Gradationally replace conventional PCR as the gold standard for a rapid-fire laboratory test for dengue contagion infections [53-55].



Fig 9: Laboratory diagnosis of dengue with respect to time of illness

4. Neutralization Test:

Neutralization test descry antibody against dengue. Neutralization test (NT) The NT is the most sensitive and specific serological test for dengue contagion opinion, and it's detected for a long period of time. Due to its high

particularity, NT can be used to identify the infecting serotype in primary dengue infections, since a fairly monotypic response is observed in the cases' serum during the convalescent phase. In secondary and tertiary infections, the determination of the infecting serotype by NT isn't always dependable. The topmost disadvantages of this system are its high cost, the long time necessary to perform it, and the associated specialized difficulties [56].

5. Tourniquet test:

The tourniquet test for capillary fragility is cited in both WHO guidelines as a individual sign for dengue. Taking only the use of an inflatable blood pressure cuff, it's quick and easy to perform. Still, a meta- analysis of 16 studies set up poor individual performance, with a pooled perceptivity and particularity of 58(95 confidence interval (CI) 43 to 71) and 71(95 CI 60 to 80), independently; albeit with a high position of publication bias.13 also, a retrospective analysis of> 28 000 tourniquet tests set up no association between test results and final laboratory verified opinion or dengue inflexibility.14 adding the individual cut- off from> 10 petechiae to> 20 petechiae didn't affect in the anticipated drop in perceptivity and increase in particularity. This poor natural correlation between dengue infection and capillary fragility may be underpinning the test's poor individual performance.13 Combined with practical considerations similar as difficulty of interpretation in different skin colours and misgivings around its positivity in other flavivirus infections, 14 it may be time to abstain the tourniquet test as a individual criterion for dengue [57-60].

Fig 10: Positive Tourniquet Test (Colour Online)

Treatment and management:

Fig 11: Dengue Vaccine (Colour Online)

The treatment for dengue contagion infection substantially Involves the use of tepid sponging for fever and antipyretics for pain or fever operation. No specific antiviral medicine is available against dengue, but several sulfated Polysaccharides uprooted from seaweeds have been Studied, and high antiviral exertion against DENV has Been observed (Damonte *et al*., 2004) [61].

1. There's no specific treatment for dengue. The focus is on treating pain symptoms. Acetaminophen (paracetamol) is frequently used to control pain. Non-steroidalanti-inflammatory medicines like ibuprofen and aspirin are avoided as they can increase the threat of bleeding. There's a vaccine called Dengvaxia for people who have had dengue at least formerly and live in places where the complaint is common [62].
2. Use pain relievers with acetaminophen and avoid drugs with aspirin which could worsen blending [62].
3. Take rest, drink plenitude of fluids. Lately, an experimental antiviral medicine, curcumin (from Turmeric) and its derivations, was assessed to determine Its anti-dengue exertion. Curcumin{1,7- bis (4- hydroxy-3- Methoxyphenyl)} and its anaLogs, similar as bis- demethoxycurcumin (CC2), acyclic anaLog (CC3), and cyclohexanone analog (CC5) showed Efficacy in inhibiting DENV replication to help severe Infection(Balasubramanian *et al*., 2019) [63]. A many other experimental antiviral treatments using CP26, CDDO- me, UV-4B, ivermectin, and ketotifen are in trial and are also Facing great challenges in controlling dengue (Wellekens *et al*., 2020) [51].

Development of Vaccine:

There's presently no specific drug for dengue treatments, and forestallment Majorly relies on vector control. Thus, dengue vaccine development is urgently needed for Dengue forestallment. The development of a DENV vaccine has come a precedence in the absence of effective and sustained control of the vectors. The complex pathogenesis and ADE effect of DENV along with genomic differences over time are the main obstacles for the development of a vaccine. DENV has a high average mutation rate of 10 −3 to 10 −5 negotiation/ nucleotide/ round of replication, which might affect in the emergence of a new lineage of contagions over time (Dolan *et al*., 2021) [64]. For illustration, the emergence of a new lineage of DENV- 3 during 2006 – 2008 and the smart genotype of DENV- 2 in India in 2011 have been reported (Harapanetal. 2020) [65]. Scientists are presently developing following types of vaccines to cover people from dengue Infections 1. Live downgraded Vaccine 2. Fantastic live downgraded Vaccine 3. Inactivated vaccines 4. Recombinant sub unit vaccine 5. Viral vector 6. DNA vaccine.



Fig 12: Types of Development of Vaccines (Colour Online)

1. Live downgraded (Attenuated) Vaccine:

Live downgraded vaccines are antigenic substances composed of a living pathogen, but the pathogen is altered to be less malign or avirulent [66]. Live downgraded vaccines show the advantages of delivering a set of defensive antigens and of furnishing long- term vulnerable protectivity [66]. Several live dengue downgraded vaccines have been made with recombinant DNA technology, similar as the fantastic unheroic fever 17D contagion- tetravalent dengue vaccine (CYD-TDV), the recombinant DENV- 4 mutant bearing a 30- nucleotide omission vaccine (rDEN4 Δ 30), and the tetra-live downgraded contagion dengue vaccine (DENVax) [67].

2. Fantastic live downgraded Vaccine:

The clinically developed dengue vaccine, CYD- TDV (Dengvaxia ®) (Sanofi, Paris, France), Complying with the International Guidelines for New Vaccines (68) has been certified by several Dengue- endemic countries in Asia and Latin America for use in people over 9 times old [69]. This vaccine was constructed by replacing the prM/ E RNAs of the YF17D (pusillanimous fever contagion vaccine Strain) with the Corresponding sequences of the four dengue serotypes [70]. It has been observed in clinical trials that Vaccination with CYD- TDV is more effective among people over 9 times old [71]. The vaccine- stimulated immunity lasts over to 4 times, and the contagion serotype, age, and dengue sera status of the existent before Vaccination feel to affect the vaccine effectivenesss [69]. ChimeriVax- Dengue (Sanofi Pasteur, Lyon, France) Elicits antibodies only to dengue [72]. Current conditions for the development of live viral vaccines (including

pusillanimous Fever 17D) produced from potentially neurotropic wild- type Contagions, include tests for neurovirulence in inhuman Primates [73]. The tetravalent fantastic pusillanimous fever contagion- DENV (CYD) vaccine is the first licensed dengue vaccine that has recently been approved for clinical use in Mexico, Thailand, Brazil, El Salvador, and Costa Rica (Aguiaretal. 2016; Prompetcharaetal. 2019) [74].

3. Inactivated Virus Vaccines:

Inactivated vaccines are antigenic substances composed of inactivated material from a pathogen (similar as contagion or bacterium) which can evoke protectivity against the live pathogen [75]. DENV2 inactivated vaccine named S16803 was developed by formalin inactivation and sucrose centrifugal sanctification and demonstrated its effectiveness in rhesus monkeys [75, 76]. The immunogenicity of the recombinant subunit protein vaccine (R80E) and live downgraded vaccine (DENV2 PDK- 50) was compared with the inactivated vaccine S16803 in rhesus monkeys, and it was set up that only DENV2 PDK- 50 can produce stable titers of antibodies [77]. Inactivated dengue contagion vaccine uses C, M, E, and NS1 protein factors as antigens to Stimulate impunity, but compound vaccines arouse better protectivity than single-type vaccines. Compared with live downgraded vaccines, inactivated contagion vaccines are safer with no retired peril of Reactivation and better controlled vulnerable balance. Whole- contagion inactivated vaccines have two major advantages over live downgraded contagion vaccines. First, it isn't possible for inactivated vaccines to revert to a further Pathogenic phenotype; second, induction of a balanced Antibody response is easier to attain [78].

4. Recombinant submit vaccines:

Recombinant subunit vaccines are antigenic proteins expressed by prokaryotic or eukaryotic cells to stimulate long- lasting defensive/ remedial vulnerable responses [79-81]. Expression of the recombinant dengue proteins in E. Coli is fairly easy, but meanwhile, there are some problems of endotoxin impurity and indecorous protein folding [82]. The recombinant envelope protein sphere III (EDIII) expressed by E. Coli and purified by essence affinity membrane chromatography was shown to successfully induce antibodies against the four serotypes of dengue in mice, and these antibodies also defended lactating mice from infection [83]. Compared with live downgraded vaccines, recombinant subunit vaccines are more likely to spark Balanced vulnerable responses against the four serotypes, reducing the prevalence of ADE effect [80, 81].

5. Viral vector vaccine:

Vaccinia contagion, adenovirus, and alphavirus vectors have been used as delivery vectors for DENV antigens in vaccine development [84]. It's recorded that prM, E, NS1, and NS2A proteins of DENV4 expressed low effectiveness in Cidofovir- resistant vaccinia (WR) strain [85]. Full- length or c-terminal abbreviated vaccinia contagion were recombinated to express DENV E protein to enhance their protectivity [86]. Still, the non-attenuated WR strain may bring safety hazards. Immunization of mice with these recombinant vaccines convinced only a low position of specific antibodies against E protein [87, 88]. Grounded on the safer modified vaccinia Ankara (MVA) contagion, MVA- DENV2 – 80E and MVA-DENV4 – 80E were also constructed, which can induce high anti-E antibodies in mice, but the former produced low situations of antibodies against DENV2 in rhesus monkeys [89]. Viral vectored vaccine is still the stylish way to induce cellular impunity, and it's hopeful to Induce stronger humoral responses. Compared with the other viral vectored vaccines, adenoviral Vectors are superior in easy inheritable manipulation, discovery of gene replication blights, and high Antigen expression.

6. DNA Vaccines:

A DNA vaccine is a plasmid containing one or further genes garbling specific antigens, which Can be fitted in vivo to express antigens and to stimulate vulnerable responses [90]. Aotusnancymae monkeys were immunized with D1ME100 intradermally and intramuscularly and also boosted at 1 and 5 months post priming; Aotus monkeys were incompletely or fully defended against DENV1 challenge at 6 months post priming [91]. In a mortal test, D1ME100 showed safe and well-tolerant goods in the first phase of vaccination and the most common side effect was mild pain or tenderheartedness at the injection point still, the immunogenicity of the vaccine was poor; only 41.6 of the subjects entering high- cure vaccination produced negativing antibodies, and no negativing antibody Response was detected in the low- cure group [92]. DNA vaccines are stable, easy to prepare, low in cost, and suitable for mass product but warrant High immunogenicity. Thus, plasmid revision with largely effective promoters, indispensable Delivery strategies, multiple boluses, andco-immunization with adjuvants may be the ways to break this Problem [93]. DNA vaccines go advantages in terms of ease of product, stability, and transport at room temperature, dropped liability of replication hindrance, and the possibility to vaccinate against multiple pathogens in a single vaccination [94].

Herbal and Home remedies for dengue fever: There are numerous ayurvedic and natural shops and home remedies are used for cure of dengue fever they're Following-

- **Neem:** Its common name is Margosa. It consists of all upstanding corridor of factory known as Azardirachta indica belonging to Family Meliacae. It's substantially set up in India, Pakistan, Bangladesh, Sri- Lanka, Thailand, Malaysia, Fiji, East Africa etc (95,96). Neem leaves, Neem oil painting are a great purifying agent and should be applied on a

damp warm cloth in Tablets of between 15 to 60 gm 2- 3 times daily. It should be noted that operation should be confined in both males and Ladies seeking gestation.

- **Coriander:** The common name is coriander fruits. It's attained from the completely dried ripe fruits of the factory Coriandrumsativum Linn. Belonging to family Umblliferae. It's substantially set up in European country basically in Russia, Hungery, Holland, In India Andhra Pradesh, and Maharashtra [95, 96]. The leaves of the coriander can be taken in the form of a alcohol to reduce the complications in dengue.
- **Papaya:** Papaya juice is a natural cure for dengue fever. The juice of Papaya splint is a sure cure for platelets insufficiency (96).
- **Dhatura:** Dhatura is attained from the flowering covers of the Dhatura metel var. It's belonging to family Solanaceae [95, 96]. Dhatura is the Ayurvedic interpretation of the belladonna. Its leaves have energy in reducing the soberness of the dengue complications. Still, the lozenge mustn't exceed 2 decigrams, or it'll lead to severe negative symptoms.

Prevention of Control:

- Primarily the dengue infection can be controlled by the control of dengue vectors which can be aimed against the immature submarine stages (naiads and nymphs) or the adult mosquitoes.
- Direct vector control measures include, use of germicides to kill the mosquitoes or help them from smelling by employing repellents.
- Environmental revision or sanitation advancements that reduce implicit larval development spots or house advancements that help mosquito entry can be used as circular vector control styles (WHO, 2009 and Kuehn, 2014) [97, 98].
- For space- spraying and larviciding bear trained labor force in discrepancy, the reduction in implicit larval development spots can be achieved with householders.
- Some of the community grounded sweats like empowering of affected and other communities through education and advocacy can rally and mount effective control operations (WHO, 2009) [97].

CONCLUSIONS

The world has seen large increases in the rates of dengue fever over the once 50 times. Although this complaint occurs most generally in the tropics and subtropics, numerous cases are now being seen among returning trippers in all areas of the world. Utmost cases can be managed with oral rehydration and close follow- up. Sometimes, the judicious use of intravenous fluids is needed to maintain sufficient urinary affair and perfusion. Indeed less generally, dengue may beget severe complaint taking blood transfusions and admission for ferocious care. While sweats are being made to develop a vaccine, forestallment presently relies primarily on reducing the niche of the vector, A. aegypti, and avoiding its bite. Habitat reduction involves dwindling mosquitos' access to stagnant bodies of water or, if that isn't possible, applying germicide.

REFERENCES

1. Brady OJ, Gething PW, Bhatt S. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoSNegl Trop Dis. 2012;6:8.
2. Saya. WHO |Dengue. [cited 2017 Jan 14]. Available from: http://www.who.int/topics/dengue/en/
3. Mayer SV, Tesh RB, Vasilakis N. The emergence of arthropod-borne viral diseases: a global prospective on dengue, chikungunya and zika fevers. Acta Trop. 2017;166:155–163.
4. Dengue: Guidelines for diagnosis, treatment, Prevention and control. New edition Geneva: World Health Organization. 2009.
5. Normile, D. (2013). Surprising new dengue virus throws a spanner in disease control efforts. *Science*, *342*(6157), 415.
6. Johansson MA, Dominici F, Glass GE. Local and Global effects of climate on dengue transmission in Puerto Rico. PLoSNegl Trop Dis. 2009;3(2):e382.
7. Ukey PM, Bondade SA, Paunipagar PV, Powar RM, Akulwar SL. Study of seroprevalance of dengue Fever in central India. Indian J Community Med. 2010;35(4):517-9.
8. Sellahewa KH (2013). Pathogenesis of dengue haemorrhagic fever and its impact on case management [Internet]. International Scholarly Research Notices. 2013 [cited 2019 Apr 30]. Available from: https://www.hindawi.com/journals/isrn/2013/571646/
9. 9.Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., et al. 2002. Structure of dengue virus: implications for flavivirus organization, maturation and fusion. Cell, 108(5): 717–725.Go to Citation Crossref PubMed ISI Google Scholar
10. Diamond M.S. and Pierson T.C. 2015. Molecular insight into dengue virus pathogenesis and its implications for disease control. Cell, 162(3): 488–492.Crossref PubMed ISI Google Scholar
11. Wu W., Bai Z., Zhou H., Tu Z., Fang M., Tang B., et al. 2011. Molecular epidemiology of dengue viruses in southern China from 1978 to 2006. Virol. J. 8(1): 322.Go to CitationCrossref PubMed ISI Google Scholar

12. World Health Organization (WHO). 1997. Dengue hemorrhagic fever. Diagnosis, treatment, prevention and control. 2nd ed. World Health Organization, Geneva.Go to Citation Google Scholar
13. Amarasinghe A., Kuritsk J.N., Letson G.W., and Margolis H.S. 2011. Dengue virus infection in Africa. Emerg. Infect. Dis. 17(8): 1349–1354.Go to CitationCrossref PubMed ISI Google Scholar
14. Were F. 2012. The dengue situation in Africa. Paediatr. Int. Child Health, 32(sup1): 18–21.Go to CitationCrossref PubMed ISI Google Scholar
15. Hanley K. A., Monath T. P., Weaver S. C., Rossi S. L., Richman R. L., Vasilakis N. Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infection, Genetics and Evolution. 2013;19:292–311. Doi: 10.1016/j.meegid.2013.03.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
16. Haddow A. D., Guzman H., Popov V. L., et al. First isolation of Aedesflavivirus in the Western Hemisphere and evidence of vertical transmission in the mosquito Aedes (Stegomyi) albopictus (Diptera: Culicidae) Virology. 2013;440(2):134–139. Doi: 10.1016/j.virol.2012.12.008. [PubMed] [CrossRef] [Google Scholar]
17. Thongyuan S., Kittayapong P. First evidence of dengue infection in domestic dogs living in different ecological settings in Thailand. PLoS One . 2017;12(8, article e0180013) doi: 10.1371/journal.pone.0180013. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Choy M. M., Sessions O. M., Gubler D. J., Ooi E. E. Production of infectious dengue virus in Aedes aegypti is dependent on the ubiquitin proteasome pathway. PLoS Neglected Tropical Diseases. 2015;9(11, article e0004227) doi: 10.1371/journal.pntd.0004227. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. Tjaden N. B., Thomas S. M., Fischer D., Beierkuhnlein C. Extrinsic incubation period of dengue: knowledge, backlog, and applications of temperature dependence. PLoS Neglected Tropical Diseases . 2013;7(6) doi: 10.1371/journal.pntd.0002207. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Huerta V., Ramos Y., Yero A., et al. Novel interactions of domain III from the envelope glycoprotein of dengue 2 virus with human plasma proteins. Journal of Proteomics . 2016;131:205–213. Doi: 10.1016/j.jprot.2015.11.003. [PubMed] [CrossRef] [Google Scholar]
21. Mori Y., Okabayashi T., Yamashita T., et al. Nuclear localization of Japanese encephalitis virus core protein enhances viral replication. Journal of Virology. 2005;79(6):3448–3458. Doi: 10.1128/JVI.79.6.3448-3458.2005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Oh W. K., Song J. Hsp70 functions as a negative regulator of West Nile virus capsid protein through direct interaction. Biochemical and Biophysical Research Communications. 2006;347(4):994–1000. Doi: 10.1016/j.bbrc.2006.06.190. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Bhuvanakantham R., Chong M. K., Ng M. L. Specific interaction of capsid protein and importin-α/β influences West Nile virus production. Biochemical and Biophysical Research Communications. 2009;389(1):63–69. Doi: 10.1016/j.bbrc.2009.08.108. [PubMed] [CrossRef] [Google Scholar]
24. Raquin V., Lambrechts L. Dengue virus replicates and accumulates in _Aedes aegypti_ salivary glands. Virology. 2017;507:75–81. Doi: 10.1016/j.virol.2017.04.009. [PubMed] [CrossRef] [Google Scholar]
25. Filomatori C. V., Lodeiro M. F., Alvarez D. E., Samsa M. M., Pietrasanta L., Gamarnik A. V. A 5' RNA element promotes dengue virus RNA synthesis on a circular genome. Genes & Development. 2006;20(16):2238–2249. Doi: 10.1101/gad.1444206. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Teo C. S. H., Chu J. J. H. Cellular vimentin regulates construction of dengue virus replication complexes through interaction with NS4A protein. Journal of Virology. 2014;88(4):1897–1913. Doi: 10.1128/JVI.01249-13. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Vaddadi Srinivas, VaddadiRadha Srinivas. "Dengue Fever: A Review Article". Journal of Evolution of Medical andDental Sciences 2015; Vol. 4, Issue 29, April 09; Page: 5048-5058, DOI: 10.14260/jemds/2015/73
28. Mitrakul, C., Poshyachinda, M., Futrakul, P., Sangkawibha, N. &Ahandrik fever. Am. J. Trop. Med. Hyg. 26, 975–984 (1977).
29. Mitrakul, C. Bleeding problem in dengue haemorrhagic fever: platelets and coagulation changes. Southeast Asian J. Trop. Med. Public Health 18, 407–412 (1987).
30. Nelson, E. R., Bierman, H. R. & Chulajata, R. Hematologic findings in the 1960 hemorrhagic fever epidemic (dengue) in Thailand. Am. J. Trop. Med. Hyg. 13, 642–649 (1964).
31. Bierman, H. R. & Nelson, E. R. Hematodepressive virus diseases of Thailand. Ann. Intern. Med. 62, 867–883 (1965).
32. Krishnamurti, C. Mechanisms of hemorrhage in Dengue without circulatory collapse. Am. J. Trop. Med. Hyg. 65, 840–847 (2001).
33. Wills, B. A. Coagulation abnormalities in Dengue hemorrhagic fever: serial investigations In 167 Vietnamese children with dengue schock Syndrome. Clin. Infect. Dis. 35, 277–285 (2002).
34. Srikiatkhachorn, A. (2009). Plasma leakage in dengue haemorrhagic fever. *Thrombosis and haemostasis*, *102*(12), 1042-1049.
35. Lin, S. W. Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits Prothrombin activation. J. Infect. 64, 325–334 (2012)

36. Nguyen MN, Duong THK, Vu TT, Nguyen THQ, Tran Nguyen BC, Vo TL. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl AcadSci USA (2013) 10:9072–7. Doi:10.1073/pnas.1303395110 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text
37. Beckett CG, Kosasih H, Faisal I, Nurhayati Tan R, Widjaja S. Early detection of dengue infections using cluster sampling around index cases. Am J Trop Med Hyg (2005) 72:777–82. Pubmed Abstract | Pubmed Full Text
38. Reyes M, Mercado JC, Standish K, Matute JC, Ortega O, Moraga B. Index cluster study of dengue virus infection in Nicaragua. Am J Trop Med Hyg (2010) 83:683–9. Doi:10.4269/ajtmh.2010.10-0023 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text
39. Yoon IK, Rothman AL, Tannitisupawong D, Srikiatkhachorn A, Jarman RG, Aldstadt J. Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages. J Infect Dis (2012) 206:389–98. Doi:10.1093/infdis/jis357 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text
40. Gordon A, Kuan G, Mercado JC, Gresh L, Aviles W, Balmaseda A. The Nicaraguan Pediatric Dengue Cohort Study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoSNegl Trop Dis (2013) 7:e2462. Doi:10.1371/journal.pntd.0002462 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text
41. Phuong HL, de Vries PJ, Nagelkerke N. Acute undifferentiated fever in BinhThuan Province, Vietnam: Imprecise Clinical diagnosis and irrational pharmaco-Therapy. Trop Med Int Health 2006; 11:869-79.
42. Efstathiou SP, Pefanis AV, Tsiakou AG. Fever of unknown origin: Discrimination Between infectious and non-infectious Causes. Eur J Intern Med 2010; 21: 137-43.
43. Abrahamsen SK, Haugen CN, Rupali P. Fever in the tropics: Aetiology and case Fatality – a prospective observational study In a tertiary care hospital in South India. BMC Infect Dis 2013; 13: 355.
44. Petersdof RG, Beeson PB. Fever of unexplained Origin: Report on 100 cases. Medicine (Bal-Timore) 1961; 40: 1-30.
45. Durack DT, Street AC. Fever of unknown origin Reexamined and redefined. Clin Top Infect Dis 1991; 11: 35-51.
46. Thangarasu S, Natarajan P, Rajavelu P, RajagoPalan A, SeelingerDevey J. A protocol for The emergency department management Of acute undifferentiated febrile illness in India. Int J Emerg Med 2011; 4: 57.
47. Huang S-Y, Lee I-K, Wang L. Use of simple clinical and laboratory predictors to differentiate influenza from dengue and other febrile illnesses in the emergency room. BMC Infect Dis. 2014;14:623.
48. Ong, A., Sandar, M., Chen, M. I., & Sin, L. Y. (2007). Fatal dengue hemorrhagic fever in adults during a dengue epidemic in Singapore. *International journal of infectious diseases*, *11*(3), 263-267.
49. Trung DT, Thao Le TT, Dung NM. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children, PLoSNegl Trop Dis, 2012, vol. 6 pg. e1679. Google ScholarCrossrefPubMedWorldCat
50. World Health Organization, Handbook for clinical management of dengue, 2012Geneva, Switzerland WHO. Google ScholarGooglePreviewWorldCatCOPAC
51. Wellekens, K., Betrains, A., De Munter, P., and Peetermans, W. 2020. Dengue: current state one year before WHO 2010–2020 goals. Acta Clin. Belg. [Online ahead of print.]. doi:10.1080/17843286.2020.1837576. PMID:33090941.
52. Vordam V., Kuno G. Laboratory diagnosis of dengue virus infections. In DJ Guber and G Kuno (ed). Dengue and dengue hemorrhagic fever, cab international, London, United Kingdon, pp 313-34. 1997
53. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet 1998;352:971–7.
54. Baalmaseda A, Sandoval E, Perez L, Gutierrez CM, Harris E. Application of molecular typing techniques in the 1998 dengue Epidemic in Nicaragua. Am J Trop Med Hyg 1999;61:893–7.
55. Raengsakulrach B, Nisalak A, Maneekarn N, Yenchitsomanus P, Limsomwong C, Jairungsri A. Comparisons of four reverse Transcription–polymerase chain reaction procedures for the Detection of dengue virus in clinical specimens. J Virol Methods 2002;105:219–31
56. Guzman M.G. and Kouri G. Advances in dengue diagnosis. ClinDiagn Lab Immnunol 1996;3:621-7.
57. Brady OJ, Gething PW, Bhatt S. Refining the global spatial limits of Dengue virus transmission by evidence-based consensus. PLoSNegl Trop Dis. 2012;6(8):e1760.Google ScholarCrossrefPubMedWorldCat
58. Stanaway JD, Shepard DS, Undurraga EA. The global burden of dengue: An analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(6):712–23. Google ScholarCrossrefPubMedWorldCat
59. World Health Organization. Dengue and severe dengue fact sheet. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue [accessed 20 July 2019].
60. Bhatt S, Gething PW, Brady OJ. The global distribution and burden of Dengue. Nature. 2013;496(7446):504–7. Google ScholarCrossrefPubMedWorldCat
61. Damonte E.B., Matulewicz M.C., and Cerezo A.S. 2004. Sulfated seaweed polysaccharides as antiviral agents. Curr. Med. Chem. 11(18): 2399–2419. Go to Citation Crossref PubMed ISI Google Scholar
62. Bhatt, S. The global distribution and burden of dengue. Nature, 2013. 496(7446): p. 504–507.
63. Balasubramanian, A., Pilankatta, R., Teramoto, T., Sajith, A.M.,Nwulia, E., Kulkarni, A., and Padmanabhan, R. 2019. Inhibiton of dengue virus by curcuminoids. Antivir. Res. 162: 71–78. Doi:10.1016/j.antiviral.2018.12.002. PMID:30529358.

64. Dolan, P.T., Taguwa, S., Rangel, M.A., Acevedo, A., Hagai, T.,Andino, R., and Frydman, J. 2021. Principles of dengue virus evolvability derived from genotype-fitness maps in human and mosquito cells. Elife, 10: e61921. doi:10.7554/eLife.61921. PMID:33491648.
65. Harapan, H., Michie, A., Sasmono, R.T., and Imrie, A. 2020. Dengue: A minireview. Viruses, 12(8): 829. doi:10.3390/v12080829.
66. Whitehead, S.S.; Blaney, J.E.; Durbin, A.P.; Murphy, B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 5, 518–528. [CrossRef]
67. Lee, H.C.; Butler, M.; Wu, S.C. Using recombinant DNA technology for the development of live-attenuated Dengue vaccines. Enzyme Microb. Technol. 2012, 51, 67–72. [CrossRef]
68. WHO expert committee on biological standardization. World Health Organization. 2011. Available online:https://www.who.int/biologicals/expert_committee/en/ (accessed on 24 September 2019).
69. Guy, B.; Noriega, F.; Ochiai, R.L.; L'azou, M.; Delore, V.; Skipetrova, A.; Verdier, F.; Coudeville, L.;Savarino, S.; Jackson, N. A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Rev. Vaccines 2017, 7, 1–13. [CrossRef]
70. Guy, B.; Guirakhoo, F.; Barban, V.; Higgs, S.; Monath, T.P.; Lang, J. Preclinical and clinical development of yfv17d-based chimeric vaccines against dengue, west nile and japanese encephalitis viruses. Vaccine 2010, 28,632–649. [CrossRef] [PubMed]
71. Hadinegoro, S.R.; Arredondo-García, J.L.; Capeding, M.R.; Deseda, C.; Chotpitayasunondh, T.; Dietze, R.; Muhammad Ismail, H.I.; Reynales, H.; Limkittikul, K.; Rivera-Medina, D.M. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N. Engl. J. Med. 2015, 373, 1195–1206. [CrossRef] [PubMed]
72. Monath TP: Dengue and yellow fever–challenges for the development and use of vaccines. N Engl J Med 2007, 357:2222–2225.
73. Monath TP, Myers GA, Beck RA. Safety testing for Neurovirulence of novel live, attenuated flavivirus vaccines: infant Mice provide an accurate surrogate for the test in monkeys. Biologicals 2005, 33:131–144.
74. Aguiar M., Stollenwerk N., and Halstead S. B. (2016). The impact of the newly licensed dengue vaccine in endemic countries. PLoSNegl. Trop. Dis. 10(12): e0005179. Go to Citation Crossref PubMed ISI Google Scholar
75. Putnak, R.; Barvir, D.A.; Burrous, J.M.; Dubois, D.R.; D'Andrea, V.M.; Hoke, C.H.; Sadoff, J.C.; Eckels, K.H. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and Protection in mice and rhesus monkeys. J. Infect. Dis. 1996, 174, 1176–1184. [CrossRef]
76. Putnak, R.; Cassidy, K.; Conforti, N.; Lee, R.; Sollazzo, D.; Truong, T.; Ing, E.; Dubois, D.; Sparkuhl, J.; Gastle, W. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 1996, 55, 504–510. [CrossRef]
77. Robert, P.J.; Coller, B.A.; Voss, G.; Vaughn, D.W.; Clements, D.; Peters, I.; Bignami, G.; Houng, H.S.; Chen, R.C.; Barvir, D.A. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated Vaccine candidates in the rhesus macaque model. Vaccine 2005, 23, 4442–4452. [CrossRef]
78. Whitehead SS, Blaney JE, Durbin AP. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007, 5:518–528.
79. Tripathi, N.K.; Shrivastava, A. Recent Developments in Recombinant Protein-Based Dengue Vaccines.Front. Immunol. 2018, 9, 1919. [CrossRef] [PubMed]
80. Pang, E.L.; Loh, H.S. Towards development of a universal dengue vaccine—How close are we? Asian Pac. J.Trop. Med. 2017, 10, 220–228. [CrossRef] [PubMed]
81. Rahul, S.; Rajpoot, R.K.; Upasana, A.; Ankur, P.; Sathyamangalam, S.; Navin, K. Pichia pastoris-expressed Bivalent virus-like particulate vaccine induces domain iii-focused bivalent neutralizing antibodies without Antibody-dependent enhancement in vivo. Front. Microbiol. 2018, 8, 2644.
82. Berlec, A.; Štrukelj, B. Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells. J. Ind. Microbiol. Biot. 2013, 40, 257–274. [CrossRef]
83. Yang, J.; Zhang, J.; Chen, W.; Hu, Z.; Rao, X. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain iii expressed in escherichia coli. Can. J. Microbiol. 2012, 58, 369–380. [CrossRef]
84. Yauch, L.E.; Shresta, S. Dengue virus vaccine development. Adv. Virus Res. 2014, 88, 315–372.
85. Zhao, B.T.; Prince, G.; Horswood, R.; Eckels, K.; Summers, P.; Chanock, R.; Lai, C.J. Expression of dengu Virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus. J. Virol. 1987, 61,4019–4022. [CrossRef] [PubMed]
86. Men, R.H.; Bray, M.; Lai, C.J. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J. Virol. 1991, 65, 1400–1407. [CrossRef] [PubMed]
87. Bray, M.; Zhao, B.T.; Markoff, L.; Eckels, K.H.; Chanock, R.M.; Lai, C.J. Mice immunized with recombinant Vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein ns1 are Protected against fatal dengue virus encephalitis. J. Virol. 1989, 63, 2853–2856. [CrossRef] [PubMed]
88. Zhang, Y.M.; Hayes, E.P.; McCarty, T.C.; Dubois, D.R.; Summers, P.L.; Eckels, K.H.; Chanock, R.M.;Lai, C.J. Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by Baculovirus recombinant induces resistance to dengue virus encephalitis. J. Virol. 1988, 62, 3027. [CrossRef] [PubMed]

89. Men, R.; Wyatt, L.; Tokimatsu, I.; Arakaki, S.; Shameem, G.; Elkins, R.; Chanock, R.; Moss, B.; Lai, C.J. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a Truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000, 18, 3113–3122. [CrossRef]
90. Kochel, T.; Wu, S.J.; Raviprakash, K.; Hobart, P.; Hoffman, S.; Porter, K.; Hayes, C. Inoculation of plasmids Expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997, 15, 547. [CrossRef]
91. Beckett, C.G.; Tjaden, J.; Burgess, T.; Danko, J.R.; Tamminga, C.; Simmons, M.; Wu, S.J.; Sun, P.; Kochel, T.;Raviprakash, K.; et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011, 29, 960–968. [CrossRef] [PubMed]
92. Danko, J.R.; Beckett, C.G.; Porter, K.R. Development of dengue dna vaccines. Vaccine 2011, 29, 7261–7266. [CrossRef]
93. Sridhar, S.; Luedtke, A.; Langevin, E.; Zhu, M.; Bonaparte, M.; Machabert, T.; Savarino, S.; Zambrano, B.;Moureau, A.; Khromava, A. (2018). Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. *N Engl J Med*, 379, 327–340. [CrossRef] [PubMed]
94. Whitehead SS, Blaney JE, Durbin AP. Prospects for a Dengue virus vaccine. Nat Rev Microbiol, 2007, 5:518–528.
95. Kokate, C. K., Purohit, A. P., & Gokhale, S. P. Pharmacognosy 26th Edition published by Nirali Prakashan. 348, 581,594.
96. Mohammad Ali. Textbook of pharmacognosy 2nd edition published by CBS publishers and distributors. 380, 381, 325.
97. WHO. (2009). Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. New ed. Geneva, Switzerland: WHO. 1-160.
98. Kuehn, B. M. (2014). Chikungunya virus Transmission found in the United States: US health authorities brace for wider Spread. *The Journal of the American Medical Association*, 27, 776-777.
99. Brady, O. J. (2012). Refining the global spatial limits of dengue virus transmission by evidence-based consensus. *PLOS Neglected Tropical Diseases, 6*(8), e1760. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue#:~:text=There%20is%20no%20specific%20treatment%20for%20dengue.,increase%20the%20risk%20of%20bleeding